{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T22:25:28Z","timestamp":1747175128882,"version":"3.40.5"},"reference-count":124,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Kidney Disease and Health"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1053\/j.akdh.2024.02.001","type":"journal-article","created":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T09:04:02Z","timestamp":1722243842000},"page":"334-345","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Non-Immunoglobulin Amyloidosis-Mediated Kidney Disease: Emerging Understanding of Underdiagnosed Entities"],"prefix":"10.1053","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0989-0241","authenticated-orcid":false,"given":"Sabine","family":"Karam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5738-9828","authenticated-orcid":false,"given":"Amit","family":"Kaushal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7310-9689","authenticated-orcid":false,"given":"Nabil","family":"Abu Amer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7036-8423","authenticated-orcid":false,"given":"Virginie","family":"Royal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhijat","family":"KItchlu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1053\/j.akdh.2024.02.001_bib1","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/MNH.0000000000000695","article-title":"Diagnosis of amyloid beyond Congo red","volume":"30","author":"Picken","year":"2021","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"6","key":"10.1053\/j.akdh.2024.02.001_bib2","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.hoc.2020.08.002","article-title":"Renal involvement in systemic amyloidosis caused by monoclonal immunoglobulins","volume":"34","author":"Karam","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"issue":"3","key":"10.1053\/j.akdh.2024.02.001_bib3","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.kint.2022.10.028","article-title":"Renal AA amyloidosis: presentation, diagnosis, and current therapeutic options: a review","volume":"103","author":"Karam","year":"2023","journal-title":"Kidney Int"},{"issue":"Suppl 1","key":"10.1053\/j.akdh.2024.02.001_bib4","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.amjmed.2022.01.003","article-title":"Renal amyloidosis: presentation, diagnosis, and management","volume":"135","author":"Gurung","year":"2022","journal-title":"Am J Med"},{"issue":"9","key":"10.1053\/j.akdh.2024.02.001_bib5","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.2215\/CJN.10491012","article-title":"Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases","volume":"8","author":"Said","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.akdh.2024.02.001_bib6","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/ki.2014.11","article-title":"Clinical, morphologic, and genetic features of renal leukocyte chemotactic factor 2 amyloidosis","volume":"86","author":"Larsen","year":"2014","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.akdh.2024.02.001_bib7","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ccl.2021.04.010","article-title":"Advances in diagnosis and treatment of cardiac and renal amyloidosis","volume":"39","author":"Law","year":"2021","journal-title":"Cardiol Clin"},{"issue":"4","key":"10.1053\/j.akdh.2024.02.001_bib8","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/13506129.2022.2070741","article-title":"The experience of hereditary apolipoprotein A-I amyloidosis at the UK National Amyloidosis Centre","volume":"29","author":"Cohen","year":"2022","journal-title":"Amyloid"},{"issue":"2","key":"10.1053\/j.akdh.2024.02.001_bib9","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/13506129.2018.1467313","article-title":"Utility of the 18F-Florbetapir positron emission tomography in systemic amyloidosis","volume":"25","author":"Mestre-Torres","year":"2018","journal-title":"Amyloid"},{"issue":"8","key":"10.1053\/j.akdh.2024.02.001_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0256306","article-title":"Immunohistochemical typing of amyloid in fixed paraffin-embedded samples by an automatic procedure: Comparison with immunofluorescence data on fresh-frozen tissue","volume":"16","author":"Barreca","year":"2021","journal-title":"PLoS One"},{"issue":"9","key":"10.1053\/j.akdh.2024.02.001_bib11","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.mayocp.2020.06.029","article-title":"Amyloid typing by mass spectrometry in clinical Practice: a Comprehensive review of 16,175 samples","volume":"95","author":"Dasari","year":"2020","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.1053\/j.akdh.2024.02.001_bib12","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s40620-017-0426-6","article-title":"Pathology and diagnosis of renal non-AL amyloidosis","volume":"31","author":"Sethi","year":"2018","journal-title":"J Nephrol"},{"issue":"6","key":"10.1053\/j.akdh.2024.02.001_bib13","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/msj.21342","article-title":"AA amyloidosis: Mount Sinai experience, 1997-2012","volume":"79","author":"Bunker","year":"2012","journal-title":"Mt Sinai J Med"},{"issue":"4","key":"10.1053\/j.akdh.2024.02.001_bib14","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/00005792-199107000-00002","article-title":"Secondary systemic amyloidosis: response and survival in 64 patients","volume":"70","author":"Gertz","year":"1991","journal-title":"Medicine (Baltim)"},{"issue":"3","key":"10.1053\/j.akdh.2024.02.001_bib15","doi-asserted-by":"crossref","first-page":"167","DOI":"10.5414\/CN110577","article-title":"AA renal amyloidosis: clinical observations over 20 years","volume":"97","author":"Khellaf","year":"2022","journal-title":"Clin Nephrol"},{"issue":"6","key":"10.1053\/j.akdh.2024.02.001_bib16","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.rbr.2016.12.002","article-title":"Clinical outcomes and survival in AA amyloidosis patients","volume":"57","author":"Ayar","year":"2017","journal-title":"Rev Bras Reumatol Engl Ed"},{"issue":"7","key":"10.1053\/j.akdh.2024.02.001_bib17","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.2215\/CJN.13641217","article-title":"Heroin Use is associated with AA-type kidney amyloidosis in the pacific Northwest","volume":"13","author":"Sharma","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.akdh.2024.02.001_bib18","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1093\/ndt\/gfac217","article-title":"AA amyloidosis associated with cancers","volume":"38","author":"Bharati","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1053\/j.akdh.2024.02.001_bib19","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40425-018-0478-8","article-title":"Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience","volume":"7","author":"Mamlouk","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"1-2","key":"10.1053\/j.akdh.2024.02.001_bib20","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/2399369320907598","article-title":"Immune checkpoint inhibitor\u2013associated renal amyloid A amyloidosis: a case series and review of the literature","volume":"4","author":"Lapman","year":"2020","journal-title":"J Onco-Nephrol"},{"issue":"4","key":"10.1053\/j.akdh.2024.02.001_bib21","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.rdc.2018.06.004","article-title":"Secondary, AA, amyloidosis","volume":"44","author":"Papa","year":"2018","journal-title":"Rheum Dis Clin North Am"},{"issue":"3","key":"10.1053\/j.akdh.2024.02.001_bib22","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1080\/13506129.2017.1342235","article-title":"Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre","volume":"24","author":"Lane","year":"2017","journal-title":"Amyloid"},{"issue":"1","key":"10.1053\/j.akdh.2024.02.001_bib23","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.autrev.2012.07.020","article-title":"Tumour necrosis factor receptor-associated periodic syndrome (TRAPS): state of the art and future perspectives","volume":"12","author":"Cantarini","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1053\/j.akdh.2024.02.001_bib24","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/ckj\/sfu021","article-title":"Amyloid nephropathy","volume":"7","author":"Khalighi","year":"2014","journal-title":"Clin Kidney J"},{"issue":"2","key":"10.1053\/j.akdh.2024.02.001_bib25","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.kint.2021.09.007","article-title":"A mutation in the SAA1 promoter causes hereditary amyloid a amyloidosis","volume":"101","author":"Sikora","year":"2022","journal-title":"Kidney Int"},{"issue":"23","key":"10.1053\/j.akdh.2024.02.001_bib26","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1056\/NEJMoa070265","article-title":"Natural history and outcome in systemic AA amyloidosis","volume":"356","author":"Lachmann","year":"2007","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1053\/j.akdh.2024.02.001_bib27","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.humpath.2007.04.013","article-title":"Clinical and histological characteristics of renal AA amyloidosis: a retrospective study of 68 cases with a special interest to amyloid-associated inflammatory response","volume":"38","author":"Verine","year":"2007","journal-title":"Hum Pathol"},{"issue":"40","key":"10.1053\/j.akdh.2024.02.001_bib28","doi-asserted-by":"crossref","first-page":"16115","DOI":"10.1073\/pnas.1306621110","article-title":"Pathogenetic mechanisms of amyloid A amyloidosis","volume":"110","author":"Simons","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1053\/j.akdh.2024.02.001_bib29","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3109\/14397595.2013.854048","article-title":"Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases","volume":"24","author":"Okuda","year":"2014","journal-title":"Mod Rheumatol"},{"issue":"4","key":"10.1053\/j.akdh.2024.02.001_bib30","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/qjmed\/95.4.211","article-title":"Unicentric Castleman\u2019s disease complicated by systemic AA amyloidosis: a curable disease","volume":"95","author":"Lachmann","year":"2002","journal-title":"QJM"},{"issue":"4","key":"10.1053\/j.akdh.2024.02.001_bib31","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1002\/art.37827","article-title":"AA amyloidosis complicating the hereditary periodic fever syndromes","volume":"65","author":"Lane","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.akdh.2024.02.001_bib32","article-title":"Kidney transplantation in patients with AA amyloidosis: outcomes in a French multicenter cohort","author":"Schwarz","year":"2023","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1053\/j.akdh.2024.02.001_bib33","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/ki.2008.152","article-title":"Leukocyte chemotactic factor 2: a novel renal amyloid protein","volume":"74","author":"Benson","year":"2008","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.akdh.2024.02.001_bib34","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/ki.2013.558","article-title":"Characterization and outcomes of renal leukocyte chemotactic factor 2-associated amyloidosis","volume":"86","author":"Said","year":"2014","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.akdh.2024.02.001_bib35","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s00709-020-01513-0","article-title":"Renal amyloidosis: an update on diagnosis and pathogenesis","volume":"257","author":"Gupta","year":"2020","journal-title":"Protoplasma"},{"issue":"2","key":"10.1053\/j.akdh.2024.02.001_bib36","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1136\/jim-2021-002149","article-title":"LECT-2 amyloidosis: what do we know?","volume":"70","author":"Mann","year":"2022","journal-title":"J Investig Med"},{"issue":"4","key":"10.1053\/j.akdh.2024.02.001_bib37","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1159\/000506696","article-title":"The pathology of amyloidosis in Classification: a review","volume":"143","author":"Picken","year":"2020","journal-title":"Acta Haematol"},{"issue":"2","key":"10.1053\/j.akdh.2024.02.001_bib38","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1080\/13506129.2020.1722097","article-title":"Renal leukocyte chemotactic factor 2 (ALECT2)-associated amyloidosis in Chinese patients","volume":"27","author":"Li","year":"2020","journal-title":"Amyloid"},{"issue":"7","key":"10.1053\/j.akdh.2024.02.001_bib39","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.humpath.2014.02.020","article-title":"Leukocyte chemotactic factor 2 amyloidosis cannot be reliably diagnosed by immunohistochemical staining","volume":"45","author":"Paueksakon","year":"2014","journal-title":"Hum Pathol"},{"issue":"2","key":"10.1053\/j.akdh.2024.02.001_bib40","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/ki.2014.45","article-title":"Alect2 amyloidosis: primum non nocere (first, do no harm)","volume":"86","author":"Picken","year":"2014","journal-title":"Kidney Int"},{"issue":"11","key":"10.1053\/j.akdh.2024.02.001_bib41","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.2215\/CJN.12551214","article-title":"Leukocyte cell-derived Chemotaxin 2-associated amyloidosis: a recently recognized disease with distinct clinicopathologic characteristics","volume":"10","author":"Nasr","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.akdh.2024.02.001_bib42","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1053\/j.ajkd.2018.10.016","article-title":"LECT2 amyloidosis in kidney transplantation: a report of 5 cases","volume":"74","author":"Mejia-Vilet","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.akdh.2024.02.001_bib43","doi-asserted-by":"crossref","DOI":"10.1590\/1414-431x2022e12284","article-title":"Renal amyloidosis: a new time for a complete diagnosis","volume":"55","author":"Feitosa","year":"2022","journal-title":"Braz J Med Biol Res"},{"issue":"3","key":"10.1053\/j.akdh.2024.02.001_bib44","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/brain\/75.3.408","article-title":"A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves","volume":"75","author":"Andrade","year":"1952","journal-title":"Brain"},{"issue":"4","key":"10.1053\/j.akdh.2024.02.001_bib45","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/ejhf.2776","article-title":"Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy","volume":"25","author":"Porcari","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.akdh.2024.02.001_bib46","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1750-1172-8-31","article-title":"Guideline of transthyretin-related hereditary amyloidosis for clinicians","volume":"8","author":"Ando","year":"2013","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"10.1053\/j.akdh.2024.02.001_bib47","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/13506129.2015.1051219","article-title":"Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 African-Americans","volume":"22","author":"Jacobson","year":"2015","journal-title":"Amyloid"},{"issue":"3","key":"10.1053\/j.akdh.2024.02.001_bib48","first-page":"309","article-title":"Postmortem findings in primary familial amyloidosis with polyneuropathy","volume":"83","author":"Hofer","year":"1975","journal-title":"Acta Pathol Microbiol Scand"},{"issue":"8","key":"10.1053\/j.akdh.2024.02.001_bib49","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3390\/brainsci11080980","article-title":"Renal involvement in hereditary transthyretin amyloidosis: an Italian single-centre experience","volume":"11","author":"Ferraro","year":"2021","journal-title":"Brain Sci"},{"issue":"7","key":"10.1053\/j.akdh.2024.02.001_bib50","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","article-title":"Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease","volume":"15","author":"Adams","year":"2019","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"10.1053\/j.akdh.2024.02.001_bib51","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/ndt\/18.3.532","article-title":"Familial ATTR amyloidosis: microalbuminuria as a predictor of symptomatic disease and clinical nephropathy","volume":"18","author":"Lobato","year":"2003","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1053\/j.akdh.2024.02.001_bib52","first-page":"438","article-title":"Portuguese-type amyloidosis (transthyretin amyloidosis, ATTR V30M)","volume":"16","author":"Lobato","year":"2003","journal-title":"J Nephrol"},{"issue":"Suppl 1","key":"10.1053\/j.akdh.2024.02.001_bib53","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1080\/13506129.2003.12088568","article-title":"Transthyretin-derived senile systemic amyloidosis: clinicopathologic and structural considerations","volume":"10","author":"Westermark","year":"2003","journal-title":"Amyloid"},{"issue":"8","key":"10.1053\/j.akdh.2024.02.001_bib54","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2215\/CJN.08720811","article-title":"Transthyretin amyloidosis and the kidney","volume":"7","author":"Lobato","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"10.1053\/j.akdh.2024.02.001_bib55","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1093\/ckj\/sfac118","article-title":"Kidney involvement in hereditary transthyretin amyloidosis: a cohort study of 103 patients","volume":"15","author":"Solignac","year":"2022","journal-title":"Clin Kidney J"},{"issue":"2","key":"10.1053\/j.akdh.2024.02.001_bib56","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.23521","article-title":"Liver transplantation and transthyretin amyloidosis","volume":"47","author":"Benson","year":"2013","journal-title":"Muscle Nerve"},{"issue":"Suppl 2","key":"10.1053\/j.akdh.2024.02.001_bib57","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10072-020-04889-2","article-title":"Hereditary transthyretin amyloidosis overview","volume":"43","author":"Manganelli","year":"2022","journal-title":"Neurol Sci"},{"issue":"11","key":"10.1053\/j.akdh.2024.02.001_bib58","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1053\/j.akdh.2024.02.001_bib59","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1007\/s00415-013-7051-7","article-title":"Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy","volume":"260","author":"Coelho","year":"2013","journal-title":"J Neurol"},{"issue":"3","key":"10.1053\/j.akdh.2024.02.001_bib60","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1080\/13506129.2017.1357545","article-title":"Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years","volume":"24","author":"Barroso","year":"2017","journal-title":"Amyloid"},{"issue":"1","key":"10.1053\/j.akdh.2024.02.001_bib61","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.008193","article-title":"Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy","volume":"15","author":"Elliott","year":"2022","journal-title":"Circ Heart Fail"},{"issue":"sup1","key":"10.1053\/j.akdh.2024.02.001_bib62","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/13506129.2019.1583186","article-title":"Significant reduction in proteinuria after treatment with tafamidis","volume":"26","author":"Ferrer-Nadal","year":"2019","journal-title":"Amyloid"},{"issue":"2","key":"10.1053\/j.akdh.2024.02.001_bib63","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/13506129.2019.1600497","article-title":"Tafamidis dramatically improved severe proteinuria in a patient with TTR V30M hereditary ATTR amyloidosis","volume":"26","author":"Ikeda","year":"2019","journal-title":"Amyloid"},{"key":"10.1053\/j.akdh.2024.02.001_bib65","article-title":"Effect of tafamidis on renal function in patients with transthyretin amyloid cardiomyopathy in ATTR-ACT","volume":"81","author":"Sperry","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1053\/j.akdh.2024.02.001_bib66","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12883-017-0948-5","article-title":"Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy","volume":"17","author":"Adams","year":"2017","journal-title":"BMC Neurol"},{"issue":"1","key":"10.1053\/j.akdh.2024.02.001_bib67","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"issue":"422","key":"10.1053\/j.akdh.2024.02.001_bib68","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan3128","article-title":"Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis","volume":"10","author":"Richards","year":"2018","journal-title":"Sci Transl Med"},{"issue":"Supplement_B","key":"10.1053\/j.akdh.2024.02.001_bib69","doi-asserted-by":"crossref","first-page":"B79","DOI":"10.1093\/eurheartjsupp\/suad079","article-title":"Monoclonal antibodies and amyloid removal as a therapeutic strategy for cardiac amyloidosis","volume":"25","author":"Emdin","year":"2023","journal-title":"Eur Heart J Suppl"},{"issue":"1","key":"10.1053\/j.akdh.2024.02.001_bib70","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12872-021-02407-6","article-title":"Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study","volume":"22","author":"Wechalekar","year":"2022","journal-title":"BMC Cardiovasc Disord"},{"issue":"3","key":"10.1053\/j.akdh.2024.02.001_bib71","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/13506129.2022.2052838","article-title":"Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis","volume":"29","author":"Ando","year":"2022","journal-title":"Amyloid"},{"issue":"3","key":"10.1053\/j.akdh.2024.02.001_bib72","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/ng0393-252","article-title":"Hereditary renal amyloidosis associated with a mutant fibrinogen alpha-chain","volume":"3","author":"Benson","year":"1993","journal-title":"Nat Genet"},{"issue":"23","key":"10.1053\/j.akdh.2024.02.001_bib73","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMoa013354","article-title":"Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis","volume":"346","author":"Lachmann","year":"2002","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.akdh.2024.02.001_bib74","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00428-008-0619-4","article-title":"Three German fibrinogen Aalpha-chain amyloidosis patients with the p.Glu526Val mutation","volume":"453","author":"Eriksson","year":"2008","journal-title":"Virchows Arch"},{"issue":"10","key":"10.1053\/j.akdh.2024.02.001_bib75","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1093\/qjmed\/89.10.745","article-title":"The molecular basis of renal amyloidosis in Irish-American and Polish-Canadian kindreds","volume":"89","author":"Uemichi","year":"1996","journal-title":"QJM"},{"issue":"3","key":"10.1053\/j.akdh.2024.02.001_bib76","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3109\/13506129809003844","article-title":"Fibrinogen A alpha chain Leu 554: an African-American kindred with late onset renal amyloidosis","volume":"5","author":"Uemichi","year":"1998","journal-title":"Amyloid"},{"issue":"2","key":"10.1053\/j.akdh.2024.02.001_bib77","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1681\/ASN.2008060614","article-title":"Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis","volume":"20","author":"Gillmore","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.akdh.2024.02.001_bib78","article-title":"Homozygosity for the E526V mutation in fibrinogen A alpha-chain amyloidosis: the first report","volume":"2015","author":"Tavares","year":"2015","journal-title":"Case Rep Nephrol"},{"issue":"04","key":"10.1053\/j.akdh.2024.02.001_bib79","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1055\/s-0036-1571340","article-title":"Laboratory and genetic Investigation of mutations accounting for congenital fibrinogen disorders","volume":"42","author":"Neerman-Arbez","year":"2016","journal-title":"Semin Thromb Hemost"},{"key":"10.1053\/j.akdh.2024.02.001_bib80","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.biochi.2016.04.020","article-title":"Familial mutations in fibrinogen A\u03b1 (FGA) chain identified in renal amyloidosis increase in\u00a0vitro amyloidogenicity of FGA fragment","volume":"127","author":"Sivalingam","year":"2016","journal-title":"Biochimie"},{"issue":"5","key":"10.1053\/j.akdh.2024.02.001_bib81","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/qjmed\/93.5.269","article-title":"Curative hepatorenal transplantation in systemic amyloidosis caused by the Glu526Val fibrinogen \u03b1-chain variant in an English family","volume":"93","author":"Gillmore","year":"2000","journal-title":"QJM: An Int J Med"},{"issue":"3","key":"10.1053\/j.akdh.2024.02.001_bib82","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1600-6143.2005.01199.x","article-title":"Successful hepatorenal transplantation in hereditary amyloidosis caused by a Frame-Shift mutation in fibrinogen Aa -chain gene","volume":"6","author":"Mousson","year":"2006","journal-title":"Am J Transplant"},{"issue":"15","key":"10.1053\/j.akdh.2024.02.001_bib83","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1182\/blood-2009-06-223792","article-title":"Hereditary fibrinogen A alpha-chain amyloidosis: phenotypic characterization of a systemic disease and the role of liver transplantation","volume":"115","author":"Stangou","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.akdh.2024.02.001_bib84","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.ekir.2016.11.005","article-title":"Renal amyloidosis associated with 5 novel variants in the fibrinogen A alpha chain protein","volume":"2","author":"Rowczenio","year":"2017","journal-title":"Kidney Int Rep"},{"issue":"3","key":"10.1053\/j.akdh.2024.02.001_bib85","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1053\/j.ajkd.2020.02.445","article-title":"Organ transplantation in hereditary fibrinogen A \u03b1-chain amyloidosis: a case series of French patients","volume":"76","author":"Meyer","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.akdh.2024.02.001_bib86","doi-asserted-by":"crossref","DOI":"10.1177\/20543581231209207","article-title":"De Novo fibrinogen A alpha chain amyloidosis in a kidney transplant patient: case report and literature review","volume":"10","author":"Khaja","year":"2023","journal-title":"Can J Kidney Health Dis"},{"issue":"4","key":"10.1053\/j.akdh.2024.02.001_bib87","first-page":"314","article-title":"Familial systemic paramyloidosis with lattice dystrophy of the cornea, progressive cranial neuropathy, skin changes and various internal symptoms. A previously unrecognized heritable syndrome","volume":"1","author":"Meretoja","year":"1969","journal-title":"Ann Clin Res"},{"issue":"1","key":"10.1053\/j.akdh.2024.02.001_bib88","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0955-0674(99)80012-X","article-title":"Functions of gelsolin: motility, signaling, apoptosis, cancer","volume":"11","author":"Kwiatkowski","year":"1999","journal-title":"Curr Opin Cell Biol"},{"issue":"47","key":"10.1053\/j.akdh.2024.02.001_bib89","doi-asserted-by":"crossref","first-page":"33179","DOI":"10.1074\/jbc.274.47.33179","article-title":"Gelsolin, a multifunctional actin regulatory protein","volume":"274","author":"Sun","year":"1999","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1053\/j.akdh.2024.02.001_bib90","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2174\/138920308786733912","article-title":"Plasma gelsolin: function, prognostic value, and potential therapeutic use","volume":"9","author":"Bucki","year":"2008","journal-title":"Curr Protein Pept Sci"},{"issue":"48","key":"10.1053\/j.akdh.2024.02.001_bib91","doi-asserted-by":"crossref","first-page":"11370","DOI":"10.1021\/bi901368e","article-title":"The 8 and 5 kDa fragments of plasma gelsolin form amyloid fibrils by a nucleated polymerization mechanism, while the 68 kDa fragment is not amyloidogenic","volume":"48","author":"Solomon","year":"2009","journal-title":"Biochemistry"},{"issue":"2","key":"10.1053\/j.akdh.2024.02.001_bib92","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/ng1092-157","article-title":"Gelsolin-derived familial amyloidosis caused by asparagine or tyrosine substitution for aspartic acid at residue 187","volume":"2","author":"de la Chapelle","year":"1992","journal-title":"Nat Genet"},{"issue":"1","key":"10.1053\/j.akdh.2024.02.001_bib93","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13023-020-1300-5","article-title":"Finnish gelsolin amyloidosis causes significant disease burden but does not affect survival: FIN-GAR phase II study","volume":"15","author":"Schmidt","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"10.1053\/j.akdh.2024.02.001_bib94","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3109\/13506129.2014.891502","article-title":"Novel gelsolin variant as the cause of nephrotic syndrome and renal amyloidosis in a large kindred","volume":"21","author":"Efebera","year":"2014","journal-title":"Amyloid"},{"issue":"1","key":"10.1053\/j.akdh.2024.02.001_bib95","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1053\/j.ajkd.2012.07.016","article-title":"Renal amyloidosis associated with a novel sequence variant of gelsolin","volume":"61","author":"Sethi","year":"2013","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1053\/j.akdh.2024.02.001_bib96","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.kint.2016.11.017","article-title":"Clinical, biopsy, and mass spectrometry findings of renal gelsolin amyloidosis","volume":"91","author":"Sethi","year":"2017","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.akdh.2024.02.001_bib97","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1080\/07853890.2016.1177197","article-title":"Causes of death and life span in Finnish gelsolin amyloidosis","volume":"48","author":"Schmidt","year":"2016","journal-title":"Ann Med"},{"issue":"12","key":"10.1053\/j.akdh.2024.02.001_bib98","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1172\/JCI118725","article-title":"Hereditary hepatic and systemic amyloidosis caused by a new deletion\/insertion mutation in the apolipoprotein AI gene","volume":"97","author":"Booth","year":"1996","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1053\/j.akdh.2024.02.001_bib99","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3109\/13506129.2015.1077217","article-title":"Amyloid cardiomyopathy associated with a novel apolipoprotein A-I Q172P variant","volume":"22","author":"Vonberg","year":"2015","journal-title":"Amyloid"},{"issue":"6","key":"10.1053\/j.akdh.2024.02.001_bib100","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/ki.2014.389","article-title":"Tubulointerstitial nephritis is a dominant feature of hereditary apolipoprotein A-I amyloidosis","volume":"87","author":"Gregorini","year":"2015","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.akdh.2024.02.001_bib101","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/j.ajpath.2011.06.024","article-title":"Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I","volume":"179","author":"Rowczenio","year":"2011","journal-title":"Am J Pathol"},{"issue":"3","key":"10.1053\/j.akdh.2024.02.001_bib102","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2353\/jmoldx.2009.080161","article-title":"Hereditary apolipoprotein AI-associated amyloidosis in surgical pathology specimens: identification of three novel mutations in the APOA1 gene","volume":"11","author":"Eriksson","year":"2009","journal-title":"J Mol Diagn"},{"issue":"8","key":"10.1053\/j.akdh.2024.02.001_bib103","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/nep.12108","article-title":"Clinical and pathologic characteristics of hereditary apolipoprotein A-I amyloidosis in Ireland","volume":"18","author":"Traynor","year":"2013","journal-title":"Nephrology"},{"issue":"2","key":"10.1053\/j.akdh.2024.02.001_bib104","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1600-6143.2012.04326.x","article-title":"Renal transplantation in systemic amyloidosis-importance of amyloid fibril type and precursor protein abundance","volume":"13","author":"Pinney","year":"2013","journal-title":"Am J Transplant"},{"issue":"6","key":"10.1053\/j.akdh.2024.02.001_bib105","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.ekir.2017.07.009","article-title":"Hereditary renal amyloidosis associated with a novel apolipoprotein A-II variant","volume":"2","author":"Prokaeva","year":"2017","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1053\/j.akdh.2024.02.001_bib106","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1046\/j.1523-1755.2003.00047.x","article-title":"Hereditary systemic amyloidosis associated with a new apolipoprotein AII stop codon mutation Stop78Arg","volume":"64","author":"Yazaki","year":"2003","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.akdh.2024.02.001_bib107","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1006\/geno.2000.6499","article-title":"A new human hereditary amyloidosis: the result of a stop-codon mutation in the apolipoprotein AII gene","volume":"72","author":"Benson","year":"2001","journal-title":"Genomics"},{"issue":"5","key":"10.1053\/j.akdh.2024.02.001_bib108","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1046\/j.1523-1755.2001.00024.x","article-title":"Renal amyloidosis caused by a novel stop-codon mutation in the apolipoprotein A-II gene","volume":"60","author":"Yazaki","year":"2001","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.akdh.2024.02.001_bib109","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.kint.2016.04.003","article-title":"Clinical, biopsy, and mass spectrometry characteristics of renal apolipoprotein A-IV amyloidosis","volume":"90","author":"Dasari","year":"2016","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.akdh.2024.02.001_bib110","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/ki.2011.316","article-title":"Medullary amyloidosis associated with apolipoprotein A-IV deposition","volume":"81","author":"Sethi","year":"2012","journal-title":"Kidney Int"},{"issue":"12","key":"10.1053\/j.akdh.2024.02.001_bib111","first-page":"2","article-title":"Cardiac amyloidosis associated with apolipoprotein A-IV deposition diagnosed by mass spectrometry-based Proteomic analysis","volume":"6","author":"Martins","year":"2019","journal-title":"Eur J Case Rep Int Med"},{"issue":"2","key":"10.1053\/j.akdh.2024.02.001_bib112","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1681\/ASN.2015111228","article-title":"Novel type of renal amyloidosis derived from apolipoprotein-CII","volume":"28","author":"Nasr","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.akdh.2024.02.001_bib113","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.ekir.2018.04.009","article-title":"Apolipoprotein CII amyloidosis associated with p.Lys41Thr mutation","volume":"3","author":"Sethi","year":"2018","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1053\/j.akdh.2024.02.001_bib114","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12944-020-01293-9","article-title":"Apolipoprotein CIII predicts cardiovascular events in patients with coronary artery disease: a prospective observational study","volume":"19","author":"Katzmann","year":"2020","journal-title":"Lipids Health Dis"},{"key":"10.1053\/j.akdh.2024.02.001_bib115","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10353","article-title":"D25V apolipoprotein C-III variant causes dominant hereditary systemic amyloidosis and confers cardiovascular protective lipoprotein profile","volume":"7","author":"Valleix","year":"2016","journal-title":"Nat Commun"},{"issue":"6420","key":"10.1053\/j.akdh.2024.02.001_bib116","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/362553a0","article-title":"Human lysozyme gene mutations cause hereditary systemic amyloidosis","volume":"362","author":"Pepys","year":"1993","journal-title":"Nature"},{"issue":"12","key":"10.1053\/j.akdh.2024.02.001_bib117","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1002\/lt.20984","article-title":"Emergency liver transplantation for hereditary lysozyme amyloidosis","volume":"12","author":"Mells","year":"2006","journal-title":"Liver Transpl"},{"issue":"1","key":"10.1053\/j.akdh.2024.02.001_bib118","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/01.md.0000200467.51816.6d","article-title":"Lysozyme amyloidosis: report of 4 cases and a review of the literature","volume":"85","author":"Granel","year":"2006","journal-title":"Medicine"},{"issue":"2","key":"10.1053\/j.akdh.2024.02.001_bib119","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1681\/ASN.2016090951","article-title":"Hereditary lysozyme amyloidosis variant p.Leu102Ser associates with unique phenotype","volume":"28","author":"Nasr","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.akdh.2024.02.001_bib120","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2796.2011.02470.x","article-title":"Hereditary lysozyme amyloidosis -- phenotypic heterogeneity and the role of solid organ transplantation","volume":"272","author":"Sattianayagam","year":"2012","journal-title":"J Intern Med"},{"issue":"3","key":"10.1053\/j.akdh.2024.02.001_bib121","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1046\/j.1523-1755.2002.00205.x","article-title":"Hereditary renal amyloidosis caused by a new variant lysozyme W64R in a French family","volume":"61","author":"Valleix","year":"2002","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.akdh.2024.02.001_bib122","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.cjca.2019.12.034","article-title":"Canadian cardiovascular Society\/Canadian heart failure society Joint position statement on the evaluation and management of patients with cardiac amyloidosis","volume":"36","author":"Fine","year":"2020","journal-title":"Can J Cardiol"},{"issue":"13 Pt 1","key":"10.1053\/j.akdh.2024.02.001_bib123","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/0002-9149(85)90995-6","article-title":"Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents","volume":"55","author":"Gertz","year":"1985","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1053\/j.akdh.2024.02.001_bib124","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10741-014-9464-5","article-title":"Natural history and therapy of AL cardiac amyloidosis","volume":"20","author":"Grogan","year":"2015","journal-title":"Heart Fail Rev"},{"issue":"4S","key":"10.1053\/j.akdh.2024.02.001_bib125","first-page":"S1","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"}],"container-title":["Advances in Kidney Disease and Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949813924000399?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949813924000399?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T10:49:17Z","timestamp":1722250157000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949813924000399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":124,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2949813924000399"],"URL":"https:\/\/doi.org\/10.1053\/j.akdh.2024.02.001","relation":{},"ISSN":["2949-8139"],"issn-type":[{"type":"print","value":"2949-8139"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-Immunoglobulin Amyloidosis-Mediated Kidney Disease: Emerging Understanding of Underdiagnosed Entities","name":"articletitle","label":"Article Title"},{"value":"Advances in Kidney Disease and Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.akdh.2024.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the National Kidney Foundation, Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}